APA (7th ed.) Citation

Gantner, P., Bani-Sadr, F., Garraffo, R., Roger, P., Treger, M., Jovelin, T., . . . Rey, D. (2016). Switch to Ritonavir-Boosted versus Unboosted Atazanavir plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical Practice. PLoS ONE, 11(10), 1. https://doi.org/10.1371/journal.pone.0164240

Chicago Style (17th ed.) Citation

Gantner, Pierre, Firouze Bani-Sadr, Rodolphe Garraffo, Pierre-Marie Roger, Michèle Treger, Thomas Jovelin, Pascal Pugliese, and David Rey. "Switch to Ritonavir-Boosted Versus Unboosted Atazanavir Plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical Practice." PLoS ONE 11, no. 10 (2016): 1. https://doi.org/10.1371/journal.pone.0164240.

MLA (9th ed.) Citation

Gantner, Pierre, et al. "Switch to Ritonavir-Boosted Versus Unboosted Atazanavir Plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical Practice." PLoS ONE, vol. 11, no. 10, 2016, p. 1, https://doi.org/10.1371/journal.pone.0164240.